Chlamydophila felis (C. felis) causes chronic conjunctivitis in cats, and is frequently treated with tetracyclines. However, tetracyclines may cause gastrointestinal side effects, such as vomiting, loss of appetite, diarrhoea, and increased liver enzyme activity in some pets. We evaluated the effect of a four-week treatment regimen with roxithromycin -RXM (Rulid ® Sanofi-Aventis, France) in 14 cats with conjunctivitis that tested C. felis-positive, and exhibited doxycycline intolerance. The treatment was given for four weeks. Assessment of clinical disease was performed on Day 0 and Day 56. Changes in severity of clinical signs were assessed on a threestep scale (increased, decreased, or no changes) every week of the therapy (Days 7, 14, 21, and 28). Additionally, conjunctival swabs were collected on Days 0 and 56 from each animal, and the C. felis-count was assessed through amplification of the ompA gene by real-time PCR with fluorogenic probes and normalisation to the feline DNA signal. Animals receiving RXM improved regarding the ophtalmological parameters related to manifestation of conjunctivitis, severity of ocular discharge and nasal discharge and breathing patterns (P ≤ 0.05). A visible improvement in relation to these parameters was already observed after two weeks of RXM administration. C. felis-counts decreased in nine cats that were given RXM, but in the other five C. felis was not eliminated. Interestingly, however, aggravation of symptoms was not observed in these five animals. Further studies are needed to fully confirm that a reduction of clinical signs and pathogen counts under conditions of natural infection can be attributed to RXM treatment, since there was no control group that received placebo or another drug in this study. The present results also indicate that in some cases 28 days of RXM administration will not be sufficient to eliminate infection.
Chlamydophila felis (C. felis) is an important pathogen in feline conjunctivitis. Infected cats are frequently treated with tetracyclines (e.g., doxycycline and oxytetracycline) (Dean et al. 2005; Stephens et al. 2009; Hartmann et al. 2010) , although fluoroquinolones may also be an effective treatment (Hartmann et al. 2008 ). However, tetracyclines (especially doxycycline) may cause gastrointestinal side effects, such as vomiting, loss of appetite, diarrhoea, and increased liver enzyme activity in some pets. For example, a long-term study indicated that anorexia, diarrhoea, and vomiting occurred in 6% to 13% of cats treated with this antibiotic, with increased liver enzymes noted in 6% to 18% of cats (Schulz et al. 2011; Schulz et al. 2013) . Furthermore, German et al. (2005) described a risk of damage resulting in oesophageal strictures after doxycycline treatment, concluding that the therapy should be accompanied by water or food supplementation. Tetracycline treatment should also be avoided in pregnant queens and growing kittens (Hartmann et al. 2008) .
Roxithromycin (RXM) is a semi-synthetic macrolide antibiotic derivative of erythromycin (Koopaei et al. 2012 ) that shows high tissue penetration and activity against Rickettsia spp., Chlamydia spp., and doi: 10.17221/8534-VETMED Mycoplasma spp. (Steel et al. 2012) . RXM showed good efficacy and safety in treating genitourinary chlamydial infections, as well as in Chlamydophila pneumoniae-associated peripheral arterial occlusive disease in human medicine (Worm et al. 1989; Krayenbuehl et al. 2005) . RXM restored the epithelial defence function of the respiratory tract in chronic inflammatory diseases in rabbits (Nakano et al. 1998) . RXM also prevented the occurrence or recurrence of otitis media with effusion in guinea pigs (Sugiura et al. 1997a) . RXM was effective in treating Borrelia burgdorferi infections in experimental animals (Preac-Mursic et al. 1989) , with no hepatic first-pass effect in rats (Padovan et al. 2012) .
Macrolide therapy may have anti-inflammatory properties, as described in human patients with chronic respiratory infections (Amsden 2005) . Erythromycin, azithromycin, clarithromycin, and RXM may inhibit chemotaxis and neutrophil infiltration into the respiratory tract, thereby decreasing mucus secretion. Macrolides inhibit the production of many pro-inflammatory cytokines (interleukin -IL-1, IL-6, IL-8, and tumour necrosis factor TNF-alpha in vitro and in vivo. Macrolides also block the formation of the adhesive molecules necessary for neutrophil migration, and they enhance ciliary activity in chronic inflammatory diseases (Suqiura et al. 1997b; Tamaoki et al. 2004) .
The efficacy of RXM in treating Chlamydia, as well as its anti-inflammatory properties suggests that it might be a good alternative in the treatment of feline chlamydophilosis. Therefore, the aim of this study was to evaluate the clinical efficacy of oral RXM treatment in tetracycline-intolerant cats with chronic conjunctivitis caused by C. felis.
MATERIAL AND METHODS
This study included 14 privately owned cats with predominant conjunctivitis that were positive for C. felis by PCR, based on methodology described by Marsilio et al. (2004) . All cats were also tested by RT-PCR and PCR to determine the presence of feline herpesvirus 1 (FHV-1) and Mycoplasma felis infections, according to published protocols (Helps et al. 2003; Chalker et al. 2004 ). The owners gave their consent for participation and also answered a questionnaire. The main criterion for study inclusion was a negative response to doxycycline, including vomiting and/or diarrhoea, within the first three days of administration. Other frequent causes of the sudden appearance of these symptoms, such as dietary errors, foreign bodies, and hairballs, were excluded during anamnesis and clinical examination. The characteristics of the examined population are provided in Table 1 . A scoring system for the evaluation of clinical signs was adapted from Hartmann et al. (2008) to enable the assessment of clinical disease (Table 2 ). Each sign was assessed separately and subsequently the total score was calculated summarising the score of each signs. Clinical signs were independently assessed by the same person, with a maximum score of 18. All cats were retested to confirm C. felis infection by RT-PCR, with a less than a one-week interval between discontinuation of doxycycline treatment and sampling.
Conjunctival samples from the ventral conjunctival fornix were collected in pairs using sterile cotton-tipped swabs and prepared for RT-PCR, as described by Sykes (2005) . Briefly, DNA from each swab pair was extracted directly with the QIA Amp Ultra Sens Virus kit (Qiagen, Syngen Biotech, Wrocław, Poland). Primers specific to the C. felis ompA gene (forward primer, 5'-GAACTGCAAG CAACACCACT G-3' and reverse primer 5'-CCATTCGGCA TCTTGAAGAT G-3') were used together with a fluorogenic probe: 6-FAM-CGCTGCCGAC AGATCAAATT TTGCC-BHQ. The feline 28S rDNA gene served as the endogenous housekeeping gene for feline conjunctival cells, using the primers described by Helps et al. (2003) and the probe, CGCGCACCCT ACTGATGATG TGTTGTTGCC GCGCG, labelled with Texas red on the 5' end and the appropriate BHQ1 on the 3' end. All reactions were performed in duplicate. Each RT-PCR-reaction was performed in a 20-μl mixture containing 10 pM of each ompA gene primer, 20 pM of each 28S rDNA gene primer, 10 pM of the FAM/BHQ, and 20 pM of the Texas red/BHQ1 probes, 1 μl of template, and 10 μl of Kappa Probe FAST qPCR Master mix (Kappa Biosystems, USA). The reaction mixture was heated to 95 °C for 3 min, followed by 45 cycles of PCR consisting of 10 s at 95 °C and 30 s at 60 °C. Fluorescence was detected at the annealing step (iQ5 Multicolor Real-Time PCR Detection System, Bio-Rad Laboratories Ltd., Poland).
DNA from the vaccine 905 C. felis strain was used as a control. The relative count of C. felis DNA was doi: 10.17221/8534-VETMED calculated from the C. felis DNA signal normalised to the feline DNA signal, as described by Dean et al. (2005) and Beshir et al. (2010) . The difference between the threshold cycles Ct (ΔCt) of the C. felis ompA gene and the Ct of the feline 28 S rDNA gene was calculated using the 2 -ΔΔCt method (Livak and Schmidtgen 2001) . The change in ΔCt was calculated after a 4-week treatment (ΔΔCt), with time 0 representing the time of pre-treatment diagnostic sampling. To calculate relative C.-felis-levels, ompA levels from cat No. 1 were arbitrarily set to 1. The percent knockdown (% KD) was calculated by subtracting the normalised ΔΔCt of the ompA gene levels at Day 0 and Day 56 and multiplying by 100.
Cats were treated with an oral suspension containing 50 mg RXM (5 mg/kg body weight) every 12 h for four weeks (from Day 0 to Day 28), followed by a four-week post-treatment-period. Conjunctival swabs were collected on Days 0 and 56. Clinical exams using a scoring system were performed at the start of the study (Day 0) and at the four-week, posttreatment follow-up (Day 56). Additionally, changes in symptom severity were assessed on a three-step scale (increased, decreased, or no changes) every week of the therapy (Days 7, 14, 21, and 28).
The Wilcoxon matched pairs test (a nonparametric alternative to the t-test for dependent samples) was used to compare proportions and statistical analysis was performed in Statistica 10.0.0 (StatSoft).
The study was performed in accordance with the ethical principles of the Ethics Committee of the Wrocław University of Environmental and Life Sciences. 
RESULTS
All 14 cats from the examined group were positive for C. felis DNA on day 0. FHV-1 was detected in one cat (No. 10). Mycoplasma spp. were not detected.
All cats receiving RXM improved significantly in all parameters (Table 2) , with pre-treatment (Day 0) clinical scores of 6.71 (± 3.24) decreasing to 1.21 on Day 56 (± 1.62) (P < 0.001). In clinical examination, there was a reduction in the ocular discharge (scores changed from 2.71 on day 0 to 0.64 on day 56, P < 0.001) and conjunctivitis manifestation (2.78 on day 0 to 0.42 on Day 56, P < 0.001). Resolution of the conjunctivitis symptoms was observed in nine cats (64%) by Day 7 of RXM administration, and in all cats by Day 14. Moreover, an improvement in cats receiving RXM was also observed with respect to the severity of nasal discharge (P = 0.028) and breathing patterns (P = 0.043). Comparability of statistics for lung P < 0.001 P < 0.001 P = 0.028 P = 0.043 not analysed not analysed P < 0.001 1 0 = no discharge, 1 = unilateral, 2 = bilateral; 2 0 = no clinical signs, 1 = minor serous discharge, 2 = moderate serous to mucoid discharge, 3 = moderate mucopurulent discharge, 4 = sever mucopurulent discharge 3 0 = no clinical signs, 1 = mild conjunctival hyperaemia, 2 = moderate conjunctival hyperaemia and mild chemosis, 3 = moderate to severe conjunctival hyperaemia and moderate chemosis, 4 = severe conjunctival hyperaemia and severe chemosis 4 0 = no clinical signs, 1 = minor serous discharge, 2 = moderate serous to mucoid discharge, 3 = moderate mucopurulent discharge, 4 = sever mucopurulent discharge 5 0 = normal, 1 = mild dyspnoea, 2 = moderate to severe dyspnoea; 6 0 = normal, 1 = mild abnormal lung sounds, 2 = moderate to severe lung sounds; 7 0 = absent, 1 = occasionally, 2 = frequently *the maximum possible total pre-treatment clinical score (Day 0) = 18, (Day 56) = 18 (Figure 1 ).
DISCUSSION
The lack of standard procedures for the culture-based detection of pathogens from the Chlamydiaceae family, low recovery rates from clinical isolates, and potential heterotypic resistance to antimicrobials make diagnosis and treatment difficult. Antibiotic therapy may be inefficient against Chlamydia/Chlamydophila infections, leading to long-term infections or perturbations in the chlamydial replication cycle (Sandoz and Rockey 2010) . Treatment efficacy can also be influenced by factors such as inadequate owner compliance in administering antibiotics; contact with other cats, potentially allowing cross-contamination with Chlamydophila; or variability in exposure to other immune challenges, if the animals are outdoors.
Treatment alternatives to doxycycline for Chlamydophila have been extensively studied. Sturgess et al. (2001) described the efficacy of 19-day-treatment with amoxicillin and clavulanic acid in specific pathogen-free cats experimentally infected with a C. felis-isolate. Treatment initially reduced isolate levels and improved clinical status, but recurrence occurred in 62% of cats within 40 days, requiring an additional four weeks of treatment to eradicate the infection. Enrofloxacin (5 mg/kg, for 14 days) improved the clinical signs of conjunctivitis, but an immunofluorescent antibody test on conjunctival swabs revealed that some cats were still positive for Chlamydia/Chlamydophila spp., despite enrofloxacin levels in tears that exceeded the minimum inhibitory concentration for those pathogens (Gerhard et al. 2006) . Owen et al. (2003) described the efficacy of azithromycin for the treatment of feline chlamydophilosis. Azithromycin (10-15 mg/kg daily for three days and then twice weekly, at the mean treatment period of 20 days) also improved the clinical signs, but C. felis was re-isolated from the majority of examined cats. Initially, daily treatment with 10 mg/kg doxycycline for two weeks was the standard of care for C. felis infection. However, even a three-week treatment may be insufficient to eradicate the pathogen completely, as C. felis DNA was still detected in some animals 35 days after treatment (Dean et al. 2005) . Therefore, we selected a study design with a four-week RXM treatment and a four-week post-treatment period.
To our knowledge, this is the first clinical study in which RXM was used to treat chlamydophilosis in cats with conjunctivitis and doxycycline intoler- ance. We used a standardised clinical assessment score proposed by Hartmann et al. (2008) to allow inter-study comparison. In Hartmann and others, this score ranged from 4.5 to 4.9 on Day 0, which was lower than in our study, indicating that those animals had better initial clinical presentations. However, both studies showed similar overall improvement rates. In their study pradofloxacin therapy reduced clinical conjunctivitis during the first week of drug administration, and they observed as well as we, an improvement with respect to local effects within the conjunctiva or respiratory tract. Therefore, our four-week oral RXM regimen may be suitable for treating the clinical manifestation of chlamydial conjunctivitis in cats. A controlled, double-blinded study, performed by Hartmann et al. (2008) , involved cats receiving pradofloxacin (5 mg/kg daily for 42 days), doxycycline (5 mg/kg every 12 h) or placebo. We measured C. felis DNA levels with the same ompA RT-PCR primers (Dean et al. 2005 ) and quantification methods. In their study, of the 23 cats positive for C. felis on Day 0, 17% had pathogen-specific DNA at the end of the treatment. Some cats were still C. felispositive on Day 42, despite being negative in the RT-PCR test during the study. We found that 35.7% of cats treated with RXM remained C. felis-positive on Day 56. Dean et al. (2005) concluded that 21 days of doxycycline therapy eradicated C. felis in 53% of pathogen-free-derived cats infected with C. felis (3×10 3 infectious units of field isolate). However, the differences in infectious route (inoculation onto the conjunctiva in SPF cats vs. natural infection) and timing make comparison of these studies difficult. In some cases even longer (28 days) therapy is needed to eradicate C. felis, according to Hartmann et al. 's studies (Hartmann et al. 2008) . In naturally infected cats treated with doxycycline the initial infection level may also determine C. felis clearance. The variability in initial infection levels and inter-animal responses to therapy are a major study limitation. The long duration of infection (six to 12 months or longer) may have prevented complete Chlamydophila clearance in the five cats that tested positive at the end of the study. Three cats that showed increased C. felis counts after RXM treatment also showed mucopurulent discharge during the therapy, suggesting concomitant bacterial infection. Variability in epidemiological differences, such as the risk of re-infection from contact with carriers at home or outside, could also make interpretation difficult. Three cats that did not show reduced C. felis counts were exposed to other cats in the house, although the infection status of these other cats is unknown. One cat was permanently living outside, which may have affected its exposure to C. felis from other animals. We conclude that a limited ability to isolate cats from the environment or to change owner habits makes it difficult to rule out the contribution of environmental factors to infection or re-infection rates. There are a few possible reasons for the observed improvement of clinical signs in all cats despite the increases in C. felis counts in some individuals. The most important ones in our opinion include, potentially additional secondary bacterial pathogens involved in conjunctivitis and sensitive to RXM and/or the possibility of C. felis re-infection. The incidence of these types of re-infections during conjunctivitis (under natural conditions) is not well known and should be studied in more detail. Therefore, there is no evidence regarding the replication and quantitative analysis of C. felis in such cases.
Outcomes of RXM therapy may also be influenced by the initial doxycycline treatment. Inhibiting the normal replication cycle of Chlamydiae by transient antibiotic administration can result in persistence and subsequent long-term infection. Antibiotic treatment causes the formation of aberrant reticular bodies that continue to synthesise proteins and replicate DNA but halt cell division (Sandoz and Rockey 2010) . Doxycycline treatment was discontinued because of negative side effects in the animals, but such discontinuation may lead to chlamydial persistence in vitro, and increased difficulty in eradicating it in vivo (Sandoz and Rockey 2010) . However, the limited extent of doxycycline administration (three days) makes it difficult to assess its contribution to the persistence of the infection. Wyrick and Knight (2004) reported the appearance of azithromycin-resistant Chlamydia strains in response to penicillin exposure.
In conclusion, we report a marked clinical improvement in cats infected with C. felis receiving a four-week dosing regimen of RXM. However, RXM treatment does not guarantee the clearance of C. felis from the animals, especially, if some epidemiological factors may not be eliminated. Further studies on feline populations with control groups are necessary in order to determine the whole potential of RXM in the treatment of cats with C. felis conjunctivitis.
